The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

PERSPECTIVES

Endeavours to define optimal antithrombotic therapy after percutaneous coronary intervention

EuroIntervention 2017;13:e1386-e1391 published online e-edition December 2017. DOI: 10.4244/EIJV13I12A222

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan


Antithrombotic therapy is an adjunctive pharmacology integral to percutaneous coronary intervention (PCI) using coronary stents. In angiographic follow-up after implantation of self-expanding, stainless steel coronary stents (WALLSTENT™; Boston Scientific, Marlborough, MA, USA) in 105 patients, Serruys et al reported complete stent occlusion in 25 patients (24%)1. The antithrombotic regimen after stent implantation at that time included intravenous heparin followed by an oral vitamin K antagonist for three to six months together with aspirin and dipyridamole. This intensive antithrombotic regimen was also associated with high rates of bleeding complications. Therefore, thrombosis and bleeding were the serious limitations of coronary stenting. Subsequently, in a ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI